Dyadic International (DYAI) Stock: Buy, Sell, or Hold?
DYAI - Dyadic International, Inc.
$0.40
0.00 (-0.75%)
▼
5d:
-2.94%
30d:
-8.32%
90d:
-64.69%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When DYAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DYAI shows positive signals but monitor for confirmation. Market pricing in 22.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DYAI shows positive signals but monitor for confirmation. Market pricing in 22.7% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DYAI is currently trading at $0.40, which is considered oversold relative to its 30-day fair value range of $0.40 to $0.45. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.2) compared to its historical average (37.3). Remarkably, the market is currently pricing in an annual earnings decline of 22.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DYAI is in a strong downtrend. Immediate support is located at $0.36, while resistance sits at $0.48.
Market Sentiment: DYAI scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.50 (+1268.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DYAI is in a strong downtrend. Immediate support is located at $0.36, while resistance sits at $0.48.
Market Sentiment: DYAI scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.50 (+1268.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.40 -
$0.45
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1268.2% below Wall St target ($5.50)
- BULLISH: Bottoming setup score 61/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.40 -
$0.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.36
Resistance Level
$0.48
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.25
Wall Street Target
$5.50
(+1268.2%)
Revenue Growth (YoY)
-0.6%
Profit Margin
-200.5%
Valuation Discount vs History
-22.7% cheaper
PE vs Historical
17.3 vs 37.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.7%
(market-implied from PE analysis)
1-Year Target
$0.36
(-10%)
2-Year Target
$0.33
(-19%)
3-Year Target
$0.29
(-27%)
3-Yr Target (if PE normalizes)
(PE: 17→37)
$0.63
(+58%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.3 to 37.3
Stabilization Target:
$0.87
(+116.2%)
PE Expansion Potential:
+116.2%
Share & Embed Analysis
Last updated: October 23, 2026 4:57 PM ET
Data refreshes hourly during market hours. Next update: 5:57 PM
Data refreshes hourly during market hours. Next update: 5:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
